2023 COVERAGE
- Zanidatamab Combo Shows Activity in Heavily Pretreated, HR+, HER2+ Breast Cancer
- Neoadjuvant Treatment Combos Face Off in HER2+ Breast Cancer
- Pregnancy After Breast Cancer Treatment Is Not Contraindicated in BRCA Carriers
- Chemo-Free Regimen May Be Frontline Option for HR+, HER2+ Metastatic Breast Cancer
- Bilateral Mastectomy Did Not Decrease Risk of Death in Breast Cancer Patients With BRCA1 Mutations
- Fertility Preservation and ART Appear Safe in HR+ Breast Cancer
